Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Marsh, Wallace A ^a   Monroe, Deirdre M ^b   Brin, Mitchell F ^b,c   Gallagher, Conor J ^b  

^a SHENANDOAH UNIVERSITY   (United States)

^b ALLERGAN INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cervical dystonia; Duration of effect; OnabotulinumtoxinA

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ARTICLE; CERVICAL DYSTONIA; COST OF ILLNESS; DOSE RESPONSE; EFFECT SIZE; HEALTH CARE UTILIZATION; HUMAN; META ANALYSIS; PATIENT SATISFACTION; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT DURATION; PUBLISHING; TORTICOLLIS; TREATMENT OUTCOME;

BOTULINUM TOXINS, TYPE A; HUMANS; NEUROMUSCULAR AGENTS; PUBLICATION BIAS; TORTICOLLIS; TREATMENT OUTCOME;

EID: 84899928554     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-14-91     Document Type: Article

References (37)

1. Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord 2007, 13(7):411-416. 10.1016/j.parkreldis.2007.02.005, 17442609.
2. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995, 45(9):1743-1746. 10.1212/WNL.45.9.1743, 7675238.
3. Brashear A, Hogan P, Wooten-Watts M, Marchetti A, Magar R, Martin J. Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia. Adv Ther 2005, 22(1):49-55. 10.1007/BF02850184, 15943222.
4. BOTOX® [package insert] 2013, Irvine, CA: Allergan, Inc.
5. Zoons E, Dijkgraaf MG, Dijk JM, van Schaik IN, Tijssen MA. Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. J Neurol 2012, 259(12):2519-2526. 10.1007/s00415-012-6510-x, 3506193, 22552527.
6. Bihari K. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Curr Med Res Opin 2005, 21(3):433-438. 10.1185/030079905X36396, 15811212.
7. Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K. A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 2009, 31(5):463-466. 10.1179/174313209X405137, 19278576.
8. Naumann M, Yakovleff A, Durif F. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 2002, 249(1):57-63. 10.1007/PL00007848, 11954869.
9. Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol 2012, 35(5):208-214. 10.1097/WNF.0b013e31826538c7, 22948497.
10. Cho MK, Bero LA. Instruments for assessing the quality of drug studies published in the medical literature. JAMA 1994, 272(2):101-104. 10.1001/jama.1994.03520020027007, 8015115.
11. Pellock JM, Carman WJ, Thyagarajan V, Daniels T, Morris DL, D'Cruz O. Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review. Neurology 2012, 79(14):1482-1489. 10.1212/WNL.0b013e31826d5ec0, 22955136.
12. Crowe M, Sheppard L, Campbell A. Reliability analysis for a proposed critical appraisal tool demonstrated value for diverse research designs. J Clin Epidemiol 2012, 65(4):375-383. 10.1016/j.jclinepi.2011.08.006, 22078576.
13. Shamliyan TA, Kane RL, Ansari MT, Raman G, Berkman ND, Grant M, Janes G, Maglione M, Moher D, Nasser M, Robinson KA, Segal JB, Tsouros S. Development quality criteria to evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic diseases: pilot study of new checklists. J Clin Epidemiol 2011, 64(6):637-657. 10.1016/j.jclinepi.2010.08.006, 21071174.
14. Han HR, Kim J, Lee JE, Hedlin HK, Song H, Song Y, Kim MT. Interventions that increase use of Pap tests among ethnic minority women: a meta-analysis. Psycho-Oncology 2011, 20(4):341-351. 10.1002/pon.1754, 3741532, 20878847.
15. Xiong C, Tang Y, van Belle G, Miller JP, Launer LJ, Morris JC. Evaluating the quality of longitudinal statistical applications in original publications on Alzheimer's disease. Neuroepidemiology 2008, 30(2):112-119. 10.1159/000120024, 2857641, 18334827.
16. Draper B, Low LF. What is the effectiveness of acute hospital treatment of older people with mental disorders?. Int Psychogeriatr 2005, 17(4):539-555. 10.1017/S1041610205001663, 16185374.
17. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005, 64(11):1949-1951. 10.1212/01.WNL.0000163767.99354.C3, 15955951.
18. Camargo CH, Teive HA, Becker N, Baran MH, Scola RH, Werneck LC. Cervical dystonia: clinical and therapeutic features in 85 patients. Arq Neuropsiquiatr 2008, 66(1):15-21. 10.1590/S0004-282X2008000100005, 18392407.
19. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003, 60(7):1186-1188. 10.1212/01.WNL.0000055087.96356.BB, 12682332.
20. Maia FM, Kanashiro AK, Chien HF, Goncalves LR, Barbosa ER. Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients. Parkinsonism Relat Disord 2010, 16(1):8-11. 10.1016/j.parkreldis.2009.06.004, 19589716.
21. Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005, 20(5):592-597. 10.1002/mds.20376, 15645481.
22. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, Marttila RJ, Lundh H, Gedin S, Westergren I, Richardson A, Dott C, Cohen H. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998, 64(1):6-12. 10.1136/jnnp.64.1.6, 2169916, 9436720.
23. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002, 72(4):459-462. 1737843, 11909903.
24. Brockmann K, Schweitzer K, Beck G, Wachter T. Comparison of different preparations of botulinumtoxin A in the treatment of cervical dystonia. Neurol Asia 2012, 17:115-119.
25. Brashear A, Watts MW, Marchetti A, Magar R, Lau H, Wang L. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. Clin Ther 2000, 22(12):1516-1524. 10.1016/S0149-2918(00)83049-0, 11192142.
26. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990, 40(2):277-280. 10.1212/WNL.40.2.277, 2300249.
27. Brashear A, Ambrosius WT, Eckert GJ, Siemers ER. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 1998, 13(1):158-161. 10.1002/mds.870130130, 9452343.
28. Dubinsky RM, Gray CS, Vetere-Overfield B, Koller WC. Electromyographic guidance of botulinum toxin treatment in cervical dystonia. Clin Neuropharmacol 1991, 14(3):262-267. 10.1097/00002826-199106000-00011, 2070367.
29. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 2008, 23(10):1353-1360. 10.1002/mds.22157, 18546321.
30. Quagliato EM, Carelli EF, Viana MA. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia. Clin Neuropharmacol 2010, 33(1):22-26.
31. Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, Jankovic J. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 2013, 67:94-114.
32. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 2011, 308(1-2):103-109.
33. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, for the German Dystonia Study Group What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry 1998, 64(1):13-17. 10.1136/jnnp.64.1.13, 2169893, 9436721, for the German Dystonia Study Group.
34. Hauser RA, Truong D, Hubble J, Coleman C, Beffy JL, Chang S, Picaut P. AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies. J Neural Transm 2013, 120(2):299-307. 10.1007/s00702-012-0872-1, 22878514.
35. Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W. Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 2000, 15(1):150-153. 10.1002/1531-8257(200001)15:1<150::AID-MDS1024>3.0.CO;2-X, 10634256.
36. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990, 53(8):633-639. 10.1136/jnnp.53.8.633, 488162, 2213039.
37. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005, 65(9):1423-1429. 10.1212/01.wnl.0000183055.81056.5c, 16275831.